Effective melanoma immunotherapy with interleukin-2 delivered by a novel polymeric nanoparticle

Molecular Cancer Therapeutics

Volumn 10, Issue 6, 2011, Pages 1082-1092

  Yao, Hong ^a,b,c   Ng, Samuel S ^b   Huo, Long Fei ^c   Chow, Billy K C ^b   Shen, Zan ^c,d   Yang, Min ^b   Sze, Johnny ^b,c   Ko, Otis ^b   Li, Ming ^c   Yue, Alexander ^c   Lu, Li Wei ^b   Bian, Xiu Wu ^a   Kung, Hsiang Fu ^a,c   Lin, Marie C ^b,c  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA CYCLODEXTRIN; FOLIC ACID; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LUCIFERASE; LYMPHOTOXIN; NANOCONJUGATE; NANOPARTICLE; PLASMID VECTOR; POLYETHYLENEIMINE; POLYMER; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENICITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONJUGATE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; IN VITRO GENE TRANSFER; MELANOMA; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMID; PRIORITY JOURNAL; SINGLE DRUG DOSE; TH1 CELL; TH17 CELL; TH2 CELL; TUMOR GROWTH;

ANIMALS; BETA-CYCLODEXTRINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NANOPARTICLES; POLYETHYLENEIMINE; POLYMERS; T-LYMPHOCYTES, HELPER-INDUCER; TRANSGENES;

EID: 79958749886     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0717     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Jiaquan Xu, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Brown CK, Kirkwood JM. Medical management of melanoma. Surg Clin North Am 2003;83:283-322. (Pubitemid 36514811)
3. Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825-36.
4. Pawlik TM, Sondak VK. Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol 2003;45:245-64. (Pubitemid 36299133)
5. Eklund JW, Kuzel TM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol 2004;16:542-6. (Pubitemid 39482972)
6. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
7. Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006;12:2353s-8s.
8. Slos P, De Meyer M, Leroy P, Rousseau C, Acres B. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity. Cancer Gene Ther 2001;8:321-32. (Pubitemid 32685640)
9. Bonnekoh B, Greenhalgh DA, Chen SH, Block A, Rich SS, Krieg T, et al. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model. J Invest Dermatol 1998;110:867-71. (Pubitemid 28237690)
10. Addison CL, Bramson JL, Hitt MM, Muller WJ, Gauldie J, Graham FL. Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Ther 1998;5:1400-9. (Pubitemid 28482668)
11. Addison CL, Braciak T, Ralston R, Muller WJ, Gauldie J, Graham FL. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A 1995;92:8522-6.
12. Dummer R, Rochlitz C, Velu T, Acres B, Limacher JM, Bleuzen P, et al. Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. Mol Ther 2008;16:985-94. (Pubitemid 351587111)
13. Galanis E, Burch PA, Richardson RL, Lewis B, Pitot HC, Frytak S, et al. Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer 2004;101:2557-66. (Pubitemid 39532285)
14. Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 1999;17:3313-23. (Pubitemid 29470668)
15. Yao H, Ng SS, Tucker WO, Tsang YK, Man K, Wang XM, et al. The gene transfection efficiency of a folate-PEI600-cyclodextrin nanopolymer. Biomaterials 2009;30:5793-803.
16. Sondergaard H, Galsgaard ED, Bartholomaeussen M, Straten PT, Odum N, Skak K. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes. J Immunother 2010;33:236-49.
17. Ziegler SF, Ramsdell F, Alderson MR. The activation antigen CD69. Stem Cells 1994;12:456-65. (Pubitemid 24278225)
18. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8.
19. Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002;25:207-17. (Pubitemid 34533310)
20. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-6. (Pubitemid 36432314)
21. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, MacIsaac KD, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007;445:931-5.
22. Frank DA, Robertson MJ, Bonni A, Ritz J, Greenberg ME. Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A 1995;92:7779-83.
23. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003;299:1033-6. (Pubitemid 36222922)
24. Lal G, Zhang N, Van Der Touw W, Ding Y, Ju W, Bottinger EP, et al. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 2009;182:259-73.
25. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3 +regulatory T cells. Proc Natl Acad Sci U S A 2008;105:18460-5.
26. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9 +IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008;9:1347-55.
27. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 2009;27:485-517.
28. Liu C, Lou Y, Lizée G, Qin H, Liu S, Rabinovich B, et al. Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest 2008;3:1165-75. (Pubitemid 351364623)
29. Zaini J, Andarini S, Tahara M, Saijo Y, Ishii N, Kawakami K, et al. OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest 2007;11:3330-8. (Pubitemid 350096989)
30. Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008;26:549-51. (Pubitemid 351668040)
31. Paillard F. CpG: the double-edged sword. Hum Gene Ther 1999;10:2089-90. (Pubitemid 29416289)
32. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Tolllike receptor recognizes bacterial DNA. Nature 2000;408:740-5. (Pubitemid 32015992)
33. Bauer S, Kirschning CJ, Häcker H, Redecke V, Hausmann S, Akira S, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 2001;98:9237-42. (Pubitemid 32743900)